Jorge Miragaya-Gomez

Barcelona, CT, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

Activated glucocorticoid receptor is an estrogen receptor silencer in ER+ metastatic breast cancer.

Activated glucocorticoid receptor is an estrogen receptor silencer in ER+ metastatic breast cancer.

Journal: EMBO molecular medicine

Published: March 03, 2025

RANK Pathway Inhibition Sensitizes Triple-Negative Breast Cancer to CDK4/6 Inhibitors and Enhances Immune Response.

RANK Pathway Inhibition Sensitizes Triple-Negative Breast Cancer to CDK4/6 Inhibitors and Enhances Immune Response.

Journal: Molecular cancer therapeutics

Published: December 10, 2024

Nicotinamide N-methyltransferase sustains a core epigenetic program that promotes metastatic colonization in breast cancer.

Nicotinamide N-methyltransferase sustains a core epigenetic program that promotes metastatic colonization in breast cancer.

Journal: The EMBO journal

Published: September 08, 2022

RANK is a poor prognosis marker and a therapeutic target in ER-negative postmenopausal breast cancer.

RANK is a poor prognosis marker and a therapeutic target in ER-negative postmenopausal breast cancer.

Journal: EMBO molecular medicine

Published: August 08, 2022

RANK signaling increases after anti-HER2 therapy contributing to the emergence of resistance in HER2-positive breast cancer.

RANK signaling increases after anti-HER2 therapy contributing to the emergence of resistance in HER2-positive breast cancer.

Journal: Breast cancer research : BCR

Published: April 24, 2020

The Altered Transcriptome and DNA Methylation Profiles of Docetaxel Resistance in Breast Cancer PDX Models.

The Altered Transcriptome and DNA Methylation Profiles of Docetaxel Resistance in Breast Cancer PDX Models.

Journal: Molecular cancer research : MCR

Published: January 17, 2019

Epigenetic inactivation of the splicing RNA-binding protein CELF2 in human breast cancer.

Epigenetic inactivation of the splicing RNA-binding protein CELF2 in human breast cancer.

Journal: Oncogene

Published: December 27, 2018

Chromosome 12p Amplification in Triple-Negative/BRCA1-Mutated Breast Cancer Associates with Emergence of Docetaxel Resistance and Carboplatin Sensitivity.

Chromosome 12p Amplification in Triple-Negative/BRCA1-Mutated Breast Cancer Associates with Emergence of Docetaxel Resistance and Carboplatin Sensitivity.

Journal: Cancer research

Published: December 06, 2018

Tumor-initiating CD49f cells are a hallmark of chemoresistant triple negative breast cancer.

Tumor-initiating CD49f cells are a hallmark of chemoresistant triple negative breast cancer.

Journal: Molecular & cellular oncology

Published: May 24, 2017

Resistance to Taxanes in Triple-Negative Breast Cancer Associates with the Dynamics of a CD49f+ Tumor-Initiating Population.

Resistance to Taxanes in Triple-Negative Breast Cancer Associates with the Dynamics of a CD49f+ Tumor-Initiating Population.

Journal: Stem cell reports

Published: October 13, 2016

Stem cell-like transcriptional reprogramming mediates metastatic resistance to mTOR inhibition.

Stem cell-like transcriptional reprogramming mediates metastatic resistance to mTOR inhibition.

Journal: Oncogene

Published: March 10, 2016

RANK Signaling Blockade Reduces Breast Cancer Recurrence by Inducing Tumor Cell Differentiation.

RANK Signaling Blockade Reduces Breast Cancer Recurrence by Inducing Tumor Cell Differentiation.

Journal: Cancer research

Published: October 05, 2015

Showing 1-12 of 13

Last Updated: 09/26/2026